Bladder Cancer

Official Journal of the Bladder Cancer Advocacy Network (BCAN)

CiteScore
2022
3.1

Volume

8, 4 issues

Latest issue

8:4 online 16 December 2022

Next issue

9:1 scheduled for March 2023

Back volumes

From volume 1, 2015

ISSN print

2352-3727

ISSN online

2352-3735
Open Access
Online Only

Aims & Scope

Bladder Cancer is an international multidisciplinary journal aiming to facilitate progress in understanding the epidemiology, etiology, molecular genetics, pathogenesis, pathobiology and pharmacology of tumors of the bladder and upper urinary tract with the objective of improving diagnosis, treatment and survivorship in patients. The journal is directed primarily at researchers and clinicians working on these areas, with some content aimed at patients/patient advocates with these conditions. With this objective in mind, the journal publishes original research reports, systematic and regular reviews, short communications, and letters-to-the-editor in basic science, translational research and clinical medicine. The journal is committed to the highest ethical standards and best practices, and prospective authors are encouraged to consult the relevant author instructions and policies on the website at the time of submission as these are updated regularly to reflect changing guidelines.

Editorial Board

Editors-in-Chief

Seth P. Lerner, MD
Baylor College of Medicine
Scott Department of Urology, Houston, Texas
USA
Email: blc@iospress.com

(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathology, Pharmacology, Diagnosis, Treatment, Survivorship)

Dan Theodorescu, MD, PhD
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center, Los Angeles, California
USA
Email: blc@iospress.com

(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathology, Pharmacology, Diagnosis, Treatment, Survivorship)

Associate Editors for Reviews

Andrea B. Apolo, MD
National Cancer Institute, U.S. Department of Health and Human Services, Rockville
USA
(Molecular Genetics, Pathogenesis, Pharmacology, Diagnosis, Treatment)

Georgios Gakis, MD, PhD
University Hospital Würzburg, Department of Urology, Würzburg
Germany
(Treatment)

Nathan Lawrentschuk, MD, PhD
University of Melbourne, Department of Surgery, Victoria
Australia
(Treatment)

Associate Editor of Challenging Cases in Urothelial Cancer

Mark S. Soloway, MD
Memorial Healthcare System, Aventura
USA
(Pathogenesis, Treatment)

Associate Editors of Clinical Trials Corner

Piyush K. Agarwal, MD
University of Chicago Medicine, Chicago
USA
(Pathogenesis, Pharmacology, Treatment)

Cora N. Sternberg, MD
San Camillo and Forlanini Hospitals, Medical Oncology, Roma
Italy
(Pathogenesis, Pharmacology, Treatment)

Editor of Paper Alert

Edward M. Messing, MD
University of Rochester Medical Center, Department of Urology, Rochester
USA
(Treatment)

Associate Editors

Hikmat Al-Ahmadie, MD
Memorial Sloan-Kettering Cancer Center, Department of Pathology, New York
USA
(Epidemiology, Molecular Genetics, Pathogenesis, Pathology)

Joaquim Bellmunt, MD, PhD
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston
USA

(Treatment)

Karim Chamie, MD
University of California Los Angeles, Department of Urology, Los Angeles
USA
(Diagnosis, Treatment, Survivorship)

David J. DeGraff, PhD
Pennsylvania State University College of Medicine, Department of Pathology, Hershey
USA
(Molecular Genetics, Pathogenesis, Pathology)

Lars Dyrskjøt, PhD
Aarhus University, Department of Molecular Medicine, Aarhus
Denmark
(Etiology, Molecular Genetics, Pathogenesis)

Jason A. Efstathiou, MD, DPhil
Massachusetts General Hospital, Harvard Medical School, Radiation Oncology, Boston
USA
(Pathogenesis, Treatment)

Thomas Flaig, MD
University of Colorado, Division of Medical Oncology, Aurora
USA
(Treatment)

Donna Hansel, MD, PhD
Oregon Health & Science University, Department of Pathology & Laboratory Medicine, Portland
USA
(Pathogenesis, Pathology)

Arndt Hartmann, MD
University Erlangen-Nürnberg, Institute of Pathology, Erlangen
Germany
(Molecular Genetics, Pathogenesis, Pathology)

Rebecca Johnson, MPH
Bladder Cancer Advocacy Network (BCAN), Bethesda
USA
(Patient-Centered Outcomes Research)

Anne Kiltie, MA, DM, DSc
Rowett Institute, University of Aberdeen, Aberdeen
United Kingdom
(Molecular Genetics, Pathogenesis, Treatment)

Yair Lotan, MD
UT Southwestern Medical Center, Urology Clinic, Dallas
USA
(Pathogenesis, Treatment)

S. Bruce Malkowicz, MD
Hospital of the University of Pennsylvania, Philadelphia
USA
(Treatment)

Surena F. Matin, MD
University of Texas MD Anderson Cancer Center, Department of Urology, Division of Surgery, Houston
USA
(Molecular Genetics, Pathogenesis, Treatment)

David McConkey, PhD
Johns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Johns Hopkins University, Baltimore
USA
(Molecular Genetics, Pathogenesis)

Matt Milowsky, MD
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
USA
(Pathogenesis, Pharmacology, Treatment)

Valeria Panebianco, MD
University of Rome La Sapienza, Department of Radiological Sciences, Oncology and Pathology, Rome
Italy
(Pathology, Diagnosis, Treatment)

Francisco X. Real, MD, PhD
CNIO (Spanish National Cancer Research Centre), Molecular Oncology Programme, Madrid
Spain
(Molecular Genetics, Pathogenesis)

Bas W.G. van Rhijn, MD, PhD
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Division of Surgical Oncology, Amsterdam
The Netherlands
(Pathogenesis, Pathology, Diagnosis)

Gottfrid Sjödahl, Ph.D.
Lund University, Department of Translational Medicine, Lund
Sweden

(Molecular Genetics, Pathogenesis, Pathology)

Angela B. Smith, MD, MS, FACS
UNC-Chapel Hill School of Medicine, Department of Urology, Chapel Hill
USA
(Etiology, Pathogenesis, Treatment)

George Thalmann, MD
University of Bern, Department of Urology, Bern
Switzerland
(Molecular Genetics, Pathogenesis, Treatment)

Xue-Ru Wu, MD
New York University (NYU), Department of Urology/Pathology, New York
USA
(Molecular Genetics, Pathogenesis)

Alexandre R. Zlotta, MD, PhD
Sinai Health System, Uro-Oncology, Lunenfeld-Tanenbaum Research Institute, Toronto
Princess Margaret Cancer Centre, University Health Network, Department of Surgical Oncology, Urology, Toronto 
Canada

(Treatment)

Social Media Associate Editor

Bishoy M. Faltas, MD
Weill Cornell Medicine, New York
USA
(Etiology, Molecular Genetics, Pathogenesis, Treatment)

Assistant Social Media Editor

Kyrillus Shohdy, MD
The University of Manchester, Manchester
United Kingdom
(Molecular Genetics, Pathogenesis, Treatment)

Editorial Board

Cory Abate-Shen, PhD
Columbia University Medical Center, Department of Molecular Pharmacology and Therapeutics, New York
USA
(Etiology, Molecular Genetics)

Phillip Abbosh, MD, PhD
Fox Chase Cancer Center at Temple University Hospital, Molecular Therapeutics, Philadelphia
USA
(Diagnosis, Treatment, Survivorship)

Marko Babjuk, MD
Motol University Hospital and 2nd Faculty of Medicine, Department of Urology, Prague, Czech Republic
USA
(Treatment)

Rick Bangs, MBA, PMP, Patient Advocate, Pittsford
USA
(Survivorship)

Trinity Bivalacqua, MD, PhD
Johns Hopkins Medicine, Department of Urology, Surgery and Oncology, Baltimore
USA
(Pathology, Diagnosis, Treatment, Survivorship)

Peter Black, MD
University of British Columbia, Department of Urology, Vancouver
Canada
(Pathology, Diagnosis, Treatment, Survivorship)

Bernard Bochner, MD
Memorial Sloan-Kettering Cancer Center, Department of Urology, Surgery and Oncology, New York
USA
(Pathology, Diagnosis, Treatment, Survivorship)

James Catto, MD, PhD
The University of Sheffield, Academic Urology Unit, Sheffield
United Kingdom
(Molecular Genetics, Pathogenesis, Diagnosis, Treatment, Survivorship)

Keith Syson Chan, MD
Samuel Oschin Comprehensive Cancer Institute, Academic Pathology, Cedars-Sinai Medical Center, Los Angeles
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathology, Pharmacology)

Sam S. Chang, MD
Vanderbilt University Medical Center, Department of Urology, Nashville
USA
(Pathology, Diagnosis, Treatment, Survivorship)

Liang Cheng, MD
Indiana University, Department of Pathology & Laboratory Medicine, Indianapolis
USA
(Molecular Genetics, Pathology, Diagnosis)

Bogdan Czerniak, MD, PhD
University of Texas MD Anderson Cancer Center, Department of Pathology, Houston
USA
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathology)

Garrett M. Dancik, PhD
Eastern Connecticut State University, Department of Computer Science, Willimantic
USA
(Epidemiology, Etiology, Molecular Genetics)

Siamak Daneshmand, MD
University of Southern California, Department of Urology, Los Angeles
USA
(Pathology, Diagnosis, Treatment, Survivorship)
    
Ian D. Davis, MBBS (Hons), PhD, FRACP, FAChPM
Monash University and Eastern Health, Eastern Health Clinical School, Box Hill
Australia
(Molecular Genetics, Diagnosis, Treatment, Survivorship)

Colin P.N. Dinney, MD
University of Texas MD Anderson Cancer Center, Department of Urology, Houston
USA
(Pathogenesis, Pathology, Pharmacology, Diagnosis, Treatment, Survivorship)

Eliney Ferreira Faria, MD, PhD
Hospital Felicio Rocho, Department of Uro-oncology and Robotic Surgery, Belo Horizonte, Brazil
(Treatment)

Mario I. Fernández, MD
Cínica Alemana Universidad del Desarrollo, Department of Urology, Santiago, Chile
(Epidemiology, Diagnosis, Treatment, Survivorship)

Matthew Galsky, MD
Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York
USA
(Molecular Genetics, Pathogenesis, Pathology, Pharmacology, Diagnosis, Treatment, Survivorship)

Scott M. Gilbert, MD
H. Lee Moffitt Cancer Center & Research Institute, Department of Urology, Tampa
USA
(Pathology, Treatment, Survivorship)

Peter J. Goebell, MD, PhD
Universitätsklinikum Erlangen, Department of Urology, Erlangen
Germany
(Molecular Genetics, Pathogenesis, Pharmacology, Diagnosis, Treatment, Survivorship)

John Gore, MD
University of Washington, Department of Urology, Seattle
USA
(Treatment)

Christian Gratzke, MD
University Hospital Freiburg, Department of Urology, Freiburg, Germany
(Diagnosis, Treatment)

Sounak Gupta, MBBS, PhD
Mayo Clinic, Rochester
USA
(Molecular Genetics, Pathogenesis, Pathology)

Noah Hahn, MD
Johns Hopkins University School of Medicine, Department of Oncology and Urology, Baltimore
USA
(Pharmacology, Diagnosis, Treatment, Survivorship)

Richard Hautmann, MD
Universität Ulm, Department of Urology, Ulm, Germany
USA
(Diagnosis, Treatment, Survivorship)

Jean Heather Hoffman-Censits, MD
Johns Hopkins University
USA
(Treatment)

Jer-Tsong Hsieh, PhD
UT Southwestern Medical Center, Department of Urology, Dallas
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathology)

Molly A. Ingersoll, PhD
Institut Pasteur, Department of Immunology, Paris
France
(Pathogenesis, Pathology, Pharmacology, Treatment)
    
Ashish M. Kamat, MD
University of Texas MD Anderson Cancer Center, Department of Urology, Division of Surgery, Houston
USA
(Diagnosis, Treatment, Survivorship)

Lawrence Karsh, MD, FACS
The Urology Center of Colorado, Department of Clinical Research, Denver
USA
(Diagnosis, Treatment, Survivorship)

Wassim Kassouf, MD
McGill University Health Center, Department of Urology, Montreal
Canada
(Diagnosis, Treatment, Survivorship)
    
Lambertus (Bart) Kiemeney, PhD
Radboud University Medical Center, Department of Health Evidence, Nijmegen
The Netherlands
(Epidemiology, Etiology, Molecular Genetics, Pathology, Pharmacology)

William Kim, MD
University of North Carolina, Department of Medicine, Chapel Hill
USA
(Molecular Genetics, Pathogenesis, Pathology, Pharmacology, Diagnosis, Treatment, Survivorship)
    
Deborah W. Knapp, DVM
Purdue University, Department of Veterinary Clinical Sciences, West Lafayette
USA
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathology, Pharmacology)
    
Margaret Knowles, PhD
Leeds Institute of Cancer & Pathology, Department of Experimental Oncology, Leeds
United Kingdom
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathology)
    
Badrinath Konety, MD
University of Minnesota, Department of Urology, Minneapolis
USA
(Diagnosis, Treatment, Survivorship)
    
David J. Kwiatkowski, MD, PhD
Brigham and Women's Hospital, Harvard Medical School, Department of Medicine, Boston
USA
(Etiology, Molecular Genetics, Pathogenesis, Diagnosis)

Donald Lamm, MD
University of Arizona, Department of Surgery, Phoenix
USA
(Diagnosis, Treatment, Survivorship)

Nathan Lawrentschuk, MD, PhD
University of Melbourne, Department of Surgery, Victoria
Australia
(Pharmacology, Diagnosis, Treatment, Survivorship)

Cheryl Lee, MD
University of Michigan Hospitals, Cancer & Geriatrics Ctr, Ann Arbor
USA
(Diagnosis, Treatment, Survivorship)

Vinata Lokeshwar, PhD
Augusta University Medical College of Georgia, Department of Biochemistry and Molecular Biology, Augusta
USA
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathology, Pharmacology)
    
Nuria Malats, MD
CNIO (Spanish National Cancer Research Centre), Genetic and Molecular Epidemiology Group, Madrid
Spain
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathology)

Kazumasa Matsumoto, MD
Kitasato University, Department of Urology, Kanagawa
Japan
(Treatment)

James McKiernan, MD
Columbia University, Department of Urology, New York
USA
(Pharmacology, Diagnosis, Treatment, Survivorship)

Reza Mehrazin, MD
The Mount Sinai Hospital, Department of Urology, New York
USA
(Treatment)

Maxwell Meng, MD
University of California San Francisco, Department of Urology, San Francisco
USA
(Pathogenesis, Treatment)

Timur Mitin, MD, PhD
Oregon Health and Science University, Portland
USA
(Treatment)

Anirban P. Mitra, MD, PhD
University of Southern California, Institute of Urology, Los Angeles
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathology, Pharmacology, Diagnosis, Treatment, Survivorship)

Ofer Nativ, MD
Bnai Zion Medical Center, Department of Urology, Haifa
Israel
(Treatment)

Roman Nawroth, PhD
Klinikum rechts der Isar, Technical University of Munich, Department of Urology, Munich
Germany
(Molecular Genetics, Pathogenesis, Pharmacology, Treatment)

Matthew Nielsen, MD, UNC School of Medicine, Department of Urology, Chapel Hill
USA
(Treatment)

Hiroyuki Nishiyama, MD, PhD
University of Tsukuba, Department of Urology, Tsukuba
Japan
(Treatment)

Michael A. O'Donnell, MD
University of Iowa Carver College of Medicine, Department of Urology, Iowa City
USA
(Etiology, Pathogenesis, Pathology, Pharmacology, Diagnosis, Treatment, Survivorship)

Joan Palou Redorta, MD, PhD
Universitat Autònoma de Barcelona, Fundació Puigvert, Department of Urology, Barcelona
Spain
(Treatment)
    
Dan Petrylak, MD
Yale University, Department of Medical Oncology, New Haven
USA
(Diagnosis, Treatment, Survivorship)

Elizabeth R. Plimack, MD
Fox Chase Cancer Center, Department of Hematology/Oncology, Philadelphia
USA
(Pharmacology, Diagnosis, Treatment, Survivorship)

Kamal Pohar, MD
Ohio State University, Department of Urology, Columbus
USA
(Treatment)

Michael P. Porter, MD
University of Washington, Department of Urology, Seattle
USA
(Epidemiology, Treatment)

Ludmila Prokunina-Olsson, PhD
National Cancer Institute, Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, Bethesda
USA
(Etiology, Molecular Genetics, Pathogenesis)

Sarah P. Psutka
University of Washington, Seattle
USA
(Etiology, Treatment)

Nagireddy Putluri, Ph.D
Baylor College of Medicine, Dept. of Molecular and Cellular Biology, Houston
USA
(Molecular Genetics, Pathogenesis, Diagnosis)

François Radvanyi, PhD
Institut Curie - UMR 144 - CNRS, Department of Cell Biology and Cancer, Paris
France
(Etiology, Molecular Genetics, Pathology)

Derek Raghavan, MD, PhD
Levine Cancer Institute, Atrium Health, Charlotte
USA
(Diagnosis, Treatment, Survivorship)

Leonardo O. Reis, MD, MSc, PhD
University of Campinas, Sao Paulo
Brazil
(Treatment)

Cyrill Rentsch, MD, PhD
University Hospital Basel, Division of Urology, Basel
Switzerland
(Pathology, Diagnosis, Treatment)

Jonathan Rosenberg, MD
Memorial Sloan-Kettering Cancer Center, Department of Medical Oncology, New York
USA
(Pharmacology, Diagnosis, Treatment, Survivorship)

Arthur I. Sagalowsky, MD
UT Southwestern Medical Center, Department of Urology, Dallas
USA
(Diagnosis, Treatment, Survivorship)

Maria De Santis, MD
Charité University Hospital, Interdisciplinary GU Oncology, Department of Urology, Berlin
Germany
(Treatment)

Marta Sánchez-Carbayo, PhD
University of the Basque Country, Department of Cancer Research, Bilbao
Spain
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathology)
    
Bernd J. Schmitz-Dräger, MD, PhD
Friedrich-Alexander University, Department of Urology and Pediatric Urology, Erlangen
Germany
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathology)

Mark P. Schoenberg, MD
The Albert Einstein College of Medicine & The Montefiore Medical Center, Department of Urology, New York
USA
(Pharmacology, Diagnosis, Treatment, Survivorship)

John P. Sfakianos, MD
Urologic Oncology, Department of Urology, Icahn School of Medicine at Mount Sinai, New York
USA
(Pathogenesis, Treatment)

Shahrokh F. Shariat, MD, PhD
Medical University Vienna, Department of Urology, Vienna
Austria
(Pharmacology, Diagnosis, Treatment, Survivorship)

Eila C. Skinner, MD
Stanford University, Department of Urology, Stanford, USA
USA
(Diagnosis, Treatment, Survivorship)

Steven Christopher Smith, MD, PhD
Virginia Commonwealth University, School of Medicine, Richmond, USA
USA
(Molecular Genetics, Pathogenesis, pathology, Diagnosis, Treatment)

Gary Steinberg, MD
NYU Langone Health, Department of Urology, New York
USA
(Pharmacology, Diagnosis, Treatment, Survivorship)

Arnulf Stenzl, MD
Universitätsklinikum Tübingen, Department of Urology, Tübingen
Germany
(Pharmacology, Diagnosis, Treatment, Survivorship)

Seth Strope, MD
Baptist MD Anderson Cancer Center, Jacksonville, Florida
USA
(Treatment)

Hyun Hwan Sung, MD, PhD
Samsung Medical Center, Department of Urology, Seoul
Korea
(Treatment)

Robert Svatek, MD, MSCI
UT Health Science Center San Antonio, Department of Urology, San Antonio
USA
(Diagnosis, Treatment, Survivorship)

John A. Taylor, III, MD, MS
University of Kansas Medical Center, Department of Urology, Kansas City
USA
(Pharmacology, Diagnosis, Treatment, Survivorship)

Jennifer M. Taylor, MD, MPH
Baylor College of Medicine/DeBakey VAMC, Houston
USA
(Diagnosis, Treatment, Survivorship)

Jeremy Teoh, MD
The Chinese University of Hong Kong, Hong Kong, China
(Epidemiology, Diagnosis, Treatment)

Antonia Vlahou, PhD
Biomedical Research Foundation Academy of Athens, Department of Systems Biology, Athens
Greece
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathology)

J. Alfred Witjes, MD, PhD
Radboud University Nijmegen, Department of Urology, Nijmegen
The Netherlands
(Etiology, Molecular Genetics, Pathogenesis, Pathology, Pharmacology)

Diane Zipursky Quale, BA, JD
Bladder Cancer Advocacy Network (BCAN), Bethesda
USA
(Survivorship)

Tahlita C.M. Zuiverloon, MD PhD
Erasmus MC Cancer Institute, Department of Urology, Rotterdam
The Netherlands

Statistical and Bioinformatics Editorial Board

Michael C. Sachs, PhD
Karolinska Institute, Department of Medical Epidemiology and Biostatistics, Stockholm
Sweden
(Epidemiology)

Richard Sylvester, ScD
EORTC, Brussels
Belgium
(Epidemiology, Etiology, Molecular Genetics)

Jeremy Taylor, PhD
University of Michigan, Department of Biostatistics, Ann Arbor
USA
(Epidemiology)

Author Guidelines

By submitting my article to this journal, I agree to the Author Copyright Agreement, the IOS Press Ethics Policy, and the IOS Press Privacy Policy.

See instructions to authors.

COPYRIGHT

Copyright of your article
Authors submitting a manuscript do so on the understanding that they have read and agreed to the terms of the IOS Press Author Copyright Agreement.

Article sharing
Authors of journal articles are permitted to self-archive and share their work through institutional repositories, personal websites, and preprint servers. Authors have the right to use excerpts of their article in other works written by the authors themselves, provided that the original work is properly cited. The consent for sharing an article, in whole or in part, depends on the version of the article that is shared, where it is shared, and the copyright license under which the article is published. Please refer to the IOS Press Article Sharing Policy for further information.

Quoting from other publications
Authors, when quoting from someone else's work or when considering reproducing figures or tables from a book or journal article, should make sure that they are not infringing a copyright. Although in general authors may quote from other published works, permission should be obtained from the holder of the copyright if there will be substantial extracts or reproduction of tables, plates, or other figures. If the copyright holder is not the author of the quoted or reproduced material, it is recommended that the permission of the author should also be sought. Material in unpublished letters and manuscripts is also protected and must not be published unless permission has been obtained. Submission of a paper will be interpreted as a statement that the author has obtained all the necessary permission. A suitable acknowledgement of any borrowed material must always be made.

Please visit the IOS Press Authors page for further information.

Abstracted/Indexed in

Cabell's Guide or Directory
Embase
Google Scholar
Scopus
Web of Science: Current Contents®/Life Sciences
Web of Science: Science Citation Index-Expanded (SciSearch®)

Policy on Open Access/Article Charges

Open Access

Papers in Bladder Cancer are currently published open access with associated fees waived until the end of 2022. This means that every article, when first posted as a pre-press article to when it is included as part of an issue, is immediately, permanently, and openly available online for readers to view, download, share, and reuse.

Beginning January 1, 2023, the journal will move from its current hybrid publication model to a true gold open access journal. Therefore, authors of accepted papers submitted after that date will be required to pay an open access fee of US$500 / EUR500 to publish under the CC BY-NC 4.0 license on acceptance for publication. Authors who envisage difficulties paying the article processing charge may appeal to the  Editors-in-chief to discuss waiving the charge. Waivers are also available for corresponding authors from eligible countries as identified by Research4Life project. A fee waiver may also be available if your institution has a transformative agreement with IOS Press.

PubMedCentral deposits

This journal deposits open access articles in PubMedCentral (PMC) as part of the IOS Press Open Library but can only do so if the article received NIH funding or if any of the authors are NIH, or associated partners, employees. Please refer to the PMC Funder Deposit List at the NIH Public Access Policy for details.

Peer Review Policy

Bladder Cancer operates a rigorous, timely, blinded peer review process (single blind by default, with an option for double-blind if requested) by experts in the field. This means that the identity of the authors is known to the reviewers but the identity of the reviewers is not communicated to the authors. Please visit our reviewer guidelines for further information about how to conduct a review.

After automatic plagiarism screening through iThenticate, all submitted manuscripts are subjected to initial appraisal by the Editors-in-Chief and/or the Associate Editors.

Manuscripts that are deemed unsuitable after this initial appraisal may be rejected without external review and the author will be informed as soon as possible.

If found suitable for further consideration, manuscripts are forwarded to an Associate Editor(AE) with expertise in the area who performs an second review and if determined to be of sufficient interest, then recruits appropriate referees. The AE will invite a sufficient number of reviewers to obtain at least 3 reviews.

Reviewers are asked to recuse themselves from reviewing a submission if a conflict makes them unable to make an impartial scientific judgment or evaluation. Conflicts of interest include, but are not limited to: collaboration with the authors in the past three years; any professional or financial affiliations that may be perceived as a conflict of interest; a history of personal differences with the author(s).

The Editors-in-Chief strive to ensure a typical turnaround time of 3 months from submission to final determination of status.

Reviewers are asked to judge a paper on the basis of:

  • Significance to field
  • Relevance to journal
  • Quality of the methodology including data analysis
  • Quality of the cited literature
  • Writing style/clarity

Based on the received reviews the Associate Editor will write a decision letter, choosing one of the following categories:

  • Accept

The manuscript is suitable for publication and only requires minor polishing; thus, no further reviews are requested.

  • Minor revisions required

The authors are required to make moderate changes to their manuscript. The manuscript becomes acceptable for publication if the changes proposed by the reviewers and editors are successfully addressed. The revised manuscript will be examined by the Associate Editor and possibly sent back to all (or a selection of) reviewers for a second round of reviews. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.

  • Major revisions required

The manuscript cannot be accepted for publication in its current form. However, a major revision addressing all issues raised by the reviewers may be acceptable for publication. The revised manuscript will undergo a full second round of review. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.

  • Revise and resubmit

In its current form, the manuscript is not suitable for publication. A resubmission would require substantial revisions and is only encouraged in special cases. The resubmitted manuscript will be considered as a new submission.

  • Reject

The manuscript is rejected as it is deemed to be out of scope, not relevant, or not meeting the journal’s quality standards in terms of significance, novelty, and/or presentation.

 

The Editors-in Chief may perform a secondary review and suggest additional revisions. After final inspection and approval of the decision letter by the Editors-in-Chief the authors are notified of the decision.

Once accepted, manuscripts are normally published on-line without delay (with the date of publication indicated) and appear in the next available issue (published quarterly).

Co-authors who are also members of the Editorial Board are not involved in any way with the peer review process of articles of their (co-)authorship, and are asked to disclose this information in the Conflict of Interest section.

The Editors-in-Chief have ultimate responsibility for what is published in the journal. 

Authors may appeal decisions by contacting the Editors-in-Chief (at blc@iospress.com). 

The Editors-in-Chief aim to inform authors in writing of the result of their appeal within 14 days.

Archives of original submissions, referee reports, revisions and correspondence for both accepted and rejected manuscripts are kept indefinitely.

Newsletter: Be sure to sign up to the BLC newsletter to receive alerts of new issues and other journal news. Sign up via this link tiny.cc/BLCsignup & you can read the latest newsletter here

Science Citation Index-Expanded: As of Sep 2019, Bladder Cancer is covered in the Science Citation Index-Expanded category in the Web of Science, which will provide greater discoverability for BLC articles leading to measurable citations and the journal’s first impact factor. 

Bladder Cancer on Twitter: You can follow us on Twitter at @BladderCaJrnl – Bishoy Faltas runs the account as our social media editor, sharing our journal content and news of interest to the bladder cancer research community. The assistant social media editor is Kyrillus Shohdy.  

BCAN Partnership: In Jan 2018, a new partnership was announced between the Bladder Cancer Advocacy Network (bcan.org) and our journal Bladder Cancer – which, as of Vol.4, Iss.1, is the official journal of BCAN. Read more in the press release.
 

Latest Articles

Discover the contents of the latest journal issue:

Combination of Two T1 Substaging Systems (T1a/b/c and T1m/e) Better Predicts Tumor Outcomes in Patients with T1 High Grade Bladder Cancer
Junjie Fan, Tao Yang, Xinqi Pei, Hua Liang, Jinhai Fan

A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E
Ana Plata Bello, Wei Phin Tan, Carlos Garcia Alvarez, Félix Guerrero-Ramos, Daniel A. González-Padilla, Cajetan Nzeh, Jose Manuel de la Morena, Ignacio Gonzalez Valcarcel de Torres, Kees Hendricksen, Francisco Javier Díaz Goizueta, Julio Fernandez Del Álamo, Francesco Chiancone, Paolo Fedelini, Massimiliano Poggio, Francesco Porpiglia, Victoria C. Gonzalo Rodríguez, Javier Montero Torres, Daniel Wilby, Richard Robinson, Alejandro Sousa-Escandón, Juan León Mata, Jose L. Pontones Moreno, Francisco Delgados Molina, Miguel A. Adriazola Semino, Andrew T. Stemberger, Jesús Calleja Escudero, Joan Palou Redorta, Wei Shen Tan

Physical Activity and Health-related Quality of Life from Diagnosis to One Year After Radical Cystectomy in Patients with Bladder Cancer: A Longitudinal Cohort Study
Ann Van Hecke, Elke Rammant, Jelle Van Cauwenberg, Karel Decaestecker, Lindsay Poppe, Beth Russel, Renée Bultijnck, Maarten Albersen, Sofie Verhaeghe, Mieke Van Hemelrijck, Roos Colman, Benedicte Deforche, Valérie Fonteyne

Sustainable Development Goals

The content of this journal relates to SDG:

sdg symbolsdg symbolsdg symbol

Visit the SDG page for more information.

Supporting Diversity and Inclusion

This journal supports IOS Press' actions relating to the Sustainable Development Goals (SDGs) and commits to the Diversity and Inclusion Statement.

dark blue banner for BLC author geo data for SDGs

More information will be available in due course. Check the SDGs page for updates.  

 

BLC is the official journal of BCAN